Retraction Note: p62 improves AD-like pathology by increasing autophagy (Molecular Psychiatry, (2017), 22, 6, (865-873), 10.1038/mp.2016.139);p62 improves AD-like pathology by increasing autophagy

Molecular Psychiatry

Volumn 22, Issue 6, 2017, Pages 865-873

  Caccamo, A ^a   Ferreira, E ^a   Branca, C ^a   Oddo, S ^a,b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b ARIZONA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; SEQUESTOSOME 1; AMYLOID PRECURSOR PROTEIN;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; COGNITIVE DEFECT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE THERAPY; IN VIVO STUDY; MALE; MORRIS WATER MAZE TEST; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; TURNOVER TIME; WESTERN BLOTTING; AMYLOID PLAQUE; ANIMAL; BRAIN; DISEASE MODEL; GENETICS; HUMAN; METABOLISM; NEUROFIBRILLARY TANGLE; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; AUTOPHAGY; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; NEUROFIBRILLARY TANGLES; PLAQUE, AMYLOID; SEQUESTOSOME-1 PROTEIN;

EID: 84984622157     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/s41380-020-0854-x     Document Type: Erratum

References (48)

1. Nixon RA. The role of autophagy in neurodegenerative disease. Nat Med 2013; 19: 983-997.
2. Orr ME, Oddo S. Autophagic/lysosomal dysfunction in Alzheimer's disease. Alzheimers Res Ther 2013; 5: 53.
3. Yang DS, Stavrides P, Saito M, Kumar A, Rodriguez-Navarro JA, Pawlik M, et al. Defective macroautophagic turnover of brain lipids in the TgCRND8 Alzheimer mouse model: prevention by correcting lysosomal proteolytic deficits. Brain 2014; 137(Pt 12): 3300-3318.
4. Yang DS, Stavrides P, Mohan PS, Kaushik S, Kumar A, Ohno M, et al. Reversal of autophagy dysfunction in the TgCRND8 mouse model of Alzheimer's disease ameliorates amyloid pathologies and memory deficits. Brain 2011; 134(Pt 1): 258-277.
5. Caccamo A, Majumder S, Richardson A, Strong R, Oddo S. Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem 2010; 285: 13107-13120.
6. Majumder S, Richardson A, Strong R, Oddo S. Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One 2011; 6: e25416.
7. Keck S, Nitsch R, Grune T, Ullrich O. Proteasome inhibition by paired helical filament-Tau in brains of patients with Alzheimer's disease. J Neurochem 2003; 85: 115-122.
8. Keller JN, Hanni KB, Markesbery WR. Impaired proteasome function in Alzheimer's disease. J Neurochem 2000; 75: 436-439.
9. Gadhave K, Bolshette N, Ahire A, Pardeshi R, Thakur K, Trandafir C, et al. The ubiquitin proteasomal system: a potential target for the management of Alzheimer's disease. J Cell Mol Med 2016; 20: 1392-1407.
10. Tramutola A, Di Domenico F, Barone E, Perluigi M, Butterfield DA. It is all about (U) biquitin: role of altered ubiquitin-proteasome system and UCHL1 in Alzheimer Disease. Oxid Med Cell Longev 2016; 2016: 2756068.
11. Oddo S. The ubiquitin-proteasome system in Alzheimer's disease. J Cell Mol Med 2008; 12: 363-373.
12. Mizushima N, Noda T, Yoshimori T, Tanaka Y, Ishii T, George MD, et al. A protein conjugation system essential for autophagy. Nature 1998; 395: 395-398.
13. Jung CH, Jun CB, Ro SH, Kim YM, Otto NM, Cao J, et al. ULK-Atg13-FIP200 complexes mediate mTOR signaling to the autophagy machinery. Mol Biol Cell 2009; 20: 1992-2003.
14. Kabeya Y, Mizushima N, Ueno T, Yamamoto A, Kirisako T, Noda T, et al. LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing. EMBO J 2000; 19: 5720-5728.
15. Sarkar S, Ravikumar B, Floto RA, Rubinsztein DC. Rapamycin and mTORindependent autophagy inducers ameliorate toxicity of polyglutamineexpanded huntingtin and related proteinopathies. Cell Death Differ 2009; 16: 46-56.
16. Salminen A, Kaarniranta K, Haapasalo A, Hiltunen M, Soininen H, Alafuzoff I. Emerging role of p62/sequestosome-1 in the pathogenesis of Alzheimer's disease. Prog Neurobiol 2012; 96: 87-95.
17. Su H, Wang X. p62 stages an interplay between the ubiquitin-proteasome system and autophagy in the heart of defense against proteotoxic stress. Trends Cardiovasc Med 2011; 21: 224-228.
18. Ramesh Babu J, Lamar Seibenhener M, Peng J, Strom AL, Kemppainen R, Cox N, et al. Genetic inactivation of p62 leads to accumulation of hyperphosphorylated tau and neurodegeneration. J Neurochem 2008; 106: 107-120.
19. Kuusisto E, Salminen A, Alafuzoff I. Early accumulation of p62 in neurofibrillary tangles in Alzheimer's disease: possible role in tangle formation. Neuropathol Appl Neurobiol 2002; 28: 228-237.
20. Du Y, Wooten MC, Gearing M, Wooten MW. Age-Associated oxidative damage to the p62 promoter: implications for Alzheimer disease. Free Radic Biol Med 2009; 46: 492-501.
21. Seibenhener ML, Babu JR, Geetha T, Wong HC, Krishna NR, Wooten MW. Sequestosome 1/p62 is a polyubiquitin chain binding protein involved in ubiquitin proteasome degradation. Mol Cell Biol 2004; 24: 8055-8068.
22. Babu JR, Geetha T, Wooten MW. Sequestosome 1/p62 shuttles polyubiquitinated tau for proteasomal degradation. J Neurochem 2005; 94: 192-203.
23. Ichimura Y, Kumanomidou T, Sou YS, Mizushima T, Ezaki J, Ueno T, et al. Structural basis for sorting mechanism of p62 in selective autophagy. J Biol Chem 2008; 283: 22847-22857.
24. Johansen T, Lamark T. Selective autophagy mediated by autophagic adapter proteins. Autophagy 2011; 7: 279-296.
25. Jankowsky JL, Fadale DJ, Anderson J, Xu GM, Gonzales V, Jenkins NA, et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-Amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet 2004; 13: 159-170.
26. Branca C, Wisely EV, Hartman LK, Caccamo A, Oddo S. Administration of a selective beta2 adrenergic receptor antagonist exacerbates neuropathology and cognitive deficits in a mouse model of Alzheimer's disease. Neurobiol Aging 2014; 35: 2726-2735.
27. Tang W, Ehrlich I, Wolff SB, Michalski AM, Wolfl S, Hasan MT, et al. Faithful expression of multiple proteins via 2A-peptide self-processing: a versatile and reliable method for manipulating brain circuits. J Neurosci 2009; 29: 8621-8629.
28. Lippai M, Low P. The role of the selective adaptor p62 and ubiquitin-like proteins in autophagy. Biomed Res Int 2014; 2014: 832704.
29. Lin X, Li S, Zhao Y, Ma X, Zhang K, He X, et al. Interaction domains of p62: a bridge between p62 and selective autophagy. DNA Cell Biol 2013; 32: 220-227.
30. Duran A, Amanchy R, Linares JF, Joshi J, Abu-Baker S, Porollo A, et al. p62 is a key regulator of nutrient sensing in the mTORC1 pathway. Mol Cell 2011; 44: 134-146.
31. Caccamo A, Magri A, Medina DX, Wisely EV, Lopez-Aranda MF, Silva AJ, et al. mTOR regulates tau phosphorylation and degradation: implications for Alzheimer's disease and other tauopathies. Aging Cell 2013; 12: 370-380.
32. Caccamo A, De Pinto V, Messina A, Branca C, Oddo S. Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature. J Neurosci 2014; 34: 7988-7998.
33. Caccamo A, Branca C, Talboom JS, Shaw DM, Turner D, Ma L, et al. Reducing ribosomal protein S6 kinase 1 expression improves spatial memory and synaptic plasticity in a mouse model of Alzheimer's Disease. J Neurosci 2015; 35: 14042-14056.
34. Oddo S. The role of mTOR signaling in Alzheimer disease. Front Biosci (Schol Ed) 2012; 4: 941-952.
35. Cai Z, Chen G, He W, Xiao M, Yan LJ. Activation of mTOR: a culprit of Alzheimer's disease?. Neuropsychiatr Dis Treat 2015; 11: 1015-1030.
36. Wang C, Yu JT, Miao D, Wu ZC, Tan MS, Tan L. Targeting the mTOR signaling network for Alzheimer's disease therapy. Mol Neurobiol 2014; 49: 120-135.
37. Gal J, Strom AL, Kwinter DM, Kilty R, Zhang J, Shi P, et al. Sequestosome 1/p62 links familial ALS mutant SOD1 to LC3 via an ubiquitin-independent mechanism. J Neurochem 2009; 111: 1062-1073.
38. Zhang YB, Gong JL, Xing TY, Zheng SP, Ding W. Autophagy protein p62/SQSTM1 is involved in HAMLET-induced cell death by modulating apotosis in U87MG cells. Cell Death Dis 2013; 4: e550.
39. Koo EH, Squazzo SL. Evidence that production and release of amyloid betaprotein involves the endocytic pathway. J Biol Chem 1994; 269: 17386-17389.
40. Welzel AT, Maggio JE, Shankar GM, Walker DE, Ostaszewski BL, Li S, et al. Secreted amyloid beta-proteins in a cell culture model include N-Terminally extended peptides that impair synaptic plasticity. Biochemistry 2014; 53: 3908-3921.
41. Zatloukal K, Stumptner C, Fuchsbichler A, Heid H, Schnoelzer M, Kenner L, et al. p62 is a common component of cytoplasmic inclusions in protein aggregation diseases. Am J Pathol 2002; 160: 255-263.
42. Kuusisto E, Salminen A, Alafuzoff I. Ubiquitin-binding protein p62 is present in neuronal and glial inclusions in human tauopathies and synucleinopathies. Neuroreport 2001; 12: 2085-2090.
43. Du Y, Wooten MC, Wooten MW. Oxidative damage to the promoter region of SQSTM1/p62 is common to neurodegenerative disease. Neurobiol Dis 2009; 35: 302-310.
44. Perez SE, He B, Nadeem M, Wuu J, Ginsberg SD, Ikonomovic MD, et al. Hippocampal endosomal, lysosomal, and autophagic dysregulation in mild cognitive impairment: correlation with abeta and tau pathology. J Neuropathol Exp Neurol 2015; 74: 345-358.
45. Yu WH, Cuervo AM, Kumar A, Peterhoff CM, Schmidt SD, Lee JH, et al. Macroautophagy-A novel Beta-Amyloid peptide-generating pathway activated in Alzheimer's disease. J Cell Biol 2005; 171: 87-98.
46. Friedman LG, Qureshi YH, Yu WH. Promoting autophagic clearance: viable therapeutic targets in Alzheimer's disease. Neurotherapeutics 2015; 12: 94-108.
47. Spilman P, Podlutskaya N, Hart MJ, Debnath J, Gorostiza O, Bredesen D, et al. Inhibition of mTOR by rapamycin abolishes cognitive deficits and reduces amyloid-beta levels in a mouse model of Alzheimer's disease. PLoS One 2010; 5: e9979.
48. Steele JW, Lachenmayer ML, Ju S, Stock A, Liken J, Kim SH, et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol Psychiatry 2013; 18: 889-897.